Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-016-1321-7) contains supplementary material, which is available to authorized users.
To summarize the data published over the last 5 years in the European Union related to the health-related quality of life (HRQoL) of patients with psoriasis and its conditioning factors.
International electronic databases and gray literature were searched to identify studies conducted on patient-reported outcomes in patients with psoriasis, published in Europe between January 1, 2009 and December 31, 2013. Bibliographic references were hand-searched. Editorials, letters, commentaries, opinion papers, and studies related to specific treatments were excluded.
A total of 46 studies met the inclusion criteria, 27 of them reporting data related to HRQoL or its conditioning factors. The publications reviewed highlighted the substantial negative impact of psoriasis on patients’ HRQoL. Most of the studies that analyzed the relationship between HRQoL and sociodemographic characteristics described a relation between gender (female) and age (young patients) and poorer HRQoL. An association between HRQoL impairment and visibility of skin lesions and disease activity and severity was also established. Skin discomfort and pruritus were identified as elements that negatively influenced HRQoL. Use of biological agents had a positive impact on HRQoL and on treatment satisfaction, a better HRQoL being seen in patients treated with systemic therapies and biologics.
HRQoL has been broadly addressed in patients with psoriasis in Europe. Several disease- and patient-related factors contributed to its deterioration. Therapeutic measures with proven effectiveness in controlling disease symptoms and reducing PASI should be considered in patients with a severe disease who have a poorer HRQoL.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Supplementary material 1 (DOCX 12 kb)11136_2016_1321_MOESM1_ESM.docx
Perera, G. K., Di Meglio, P., Frank, O., & Nestle, F. O. (2012). Psoriasis. Annual Review of Pathology: Mechanisms of Disease, 7, 385–422. CrossRef
Ortonne, J. P., & Prinz, J. C. (2004). Alefacept: A novel and selective biologic agent for the treatment of chronic plaque psoriasis. The European Journal of Dermatology, 14, 41–45. PubMed
Lebwohl, M. G., Bachelez, H., Barker, J., Girolomoni, G., Kavanaugh, A., Langley, R. G., et al. (2014). Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Journal of the American Academy of Dermatology, 70(5), 871–881. CrossRefPubMed
Tan, X., Feldman, S. R., & Balkrishnan, R. (2012). Quality of life issues and measurement in patients with psoriasis. Psoriasis: Targets and Therapy, 2(1), 13–23.
Higgins, J. P. (Ed.). (2008). Cochrane handbook for systematic reviews of interventions (Vol. 5). Chichester: Wiley.
European Union. EU member countries. http://europa.eu/about-eu/countries/member-countries/. Accessed March 3, 2014.
Centre for evidence based medicine. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
Daudén, E., Conejo, J., & García-Calvo, C. (2011). Percepción del médico y paciente de la gravedad de la psoriasis, su impacto en la calidad de vida y satisfacción con la atención y el tratamiento recibido. Estudio observacional en España. Actas Dermo-Sifiliográficas, 102(4), 270–276. CrossRef
Böhm, D., Stock Gissendanner, S., Bangemann, K., Snitjer, I., Werfel, T., Weyergraf, A., et al. (2013). Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. Journal of the European Academy of Dermatology and Venereology, 27, 220–226. CrossRefPubMed
Lindberg, M., Isacson, D., & Bingefors, K. (2013). Self-reported skin diseases, quality of life and medication use: A nationwide pharmaco-epidemiological survey in Sweden. Acta Dermato-Venereologica, 94(2), 188–191. CrossRef
Daudén, E., Pujol, R. M., Sánchez-Carazo, J. L., Toribio, J., Vanaclocha, F., Puig, L., et al. (2013). Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study. Actas Dermo-Sifiliográficas, 104, 807–814. PubMed
Fernandez-Torres, R. M., Paradela, S., & Fonseca, E. (2012). Psoriasis in patients older than 65 years. A comparative study with younger adult psoriatic patients. The Journal of Nutrition, Health & Aging, 16, 586–589. CrossRef
Hernánz, J. M., Sánchez-Regaña, M., Izu, R., Mendiola, V., & García-Calvo, C. (2012). Clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: The Secuence Study. Actas Dermo-Sifiliográficas, 103(10), 897–904. CrossRef
Cozzani, E., Borrini, V., Pennella, A., Burlando, M., Cardo, P., Rebora, A., et al. (2010). The quality of life in Italian psoriatic patients treated with biological drugs. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia, 145(6), 709–712.
Pereira, M. G., Brito, L., & Smith, T. (2012). Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners. The International Journal of Behavioral Medicine, 9(3), 260–269. CrossRef
Gupta, M. A., Gupta, A. K., & Watteel, G. N. (1998). Perceived deprivation of social touch in psoriasis is associated with greater psychologic morbidity: An index of the stigma experience in dermatologic disorder. Cutis, 61, 339–342. PubMed
Palotai, T., Szepietowski, J. C., Pec, J., Arenberger, P., Giurcaneanu, C., Gyulai, R., et al. (2010). A survey of disease severity, quality of life, and treatment patterns of biologically naïve patients with psoriasis in Central and Eastern Europe. Acta Dermatovenerologica Croatica, 18(3), 151–162.
Panigalli, S., Coccarielli, D., Germi, L., Trevisan, G. P., & Veller-Fornasa, C. (2009). Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis. Journal of Biological Regulators and Homeostatic Agents, 23(2), 111–117. PubMed
Ghatnekar, O., Ljungberg, A., Wirestrand, L. E., & Svensson, A. (2012). Cost and quality of life for psoriatic patients at different degrees of severity in southern Sweden—A cross-sectional study. The European Journal of Dermatology, 22(2), 238–2345. PubMed
Ghajarzadeh, M., Ghiasi, M., & Kheirkhah, S. (2012). Associations between skin disease and quality of life: A comparision of psoriasis, vitiligo, and alopecia areata. Acta Medica Iranica, 50(7), 511–515. PubMed
Takeshita, J., Duffin, K. C., Shin, D. B., Krueger, G. G., Robertson, A. D., Troxel, A. B., et al. (2014). Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. Journal of the American Academy of Dermatology, 71(4), 633–641. CrossRefPubMedPubMedCentral
Viswanathan, H. N., Chau, D., Milmont, C. E., Yang, W., Erondu, N., Revicki, D. A., et al. (2014). Total Skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. Journal of Dermatological Treatment, 31, 1–5.
Mattei, P. L., Corey, K. C., & Kimball, A. B. (2014). Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The correlation between disease severity and psychological burden in patients treated with biological therapies. Journal of the European Academy of Dermatology and Venereology, 28, 333–337. CrossRefPubMed
Moreno-Ramírez, D., Fonseca, E., Herranz, P., & Ara, M. (2010). Realidad terapéutica de la psoriasis moderada-grave en España. Encuesta de opinión. Actas Dermo-Sifiliográficas, 101(10), 858–865. CrossRef
Hägg, D., Sundström, A., Eriksson, M., & Schimitt-Egenolf, M. (2015). Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). Journal of the European Academy of Dermatology and Venereology, 9(3), 452–456. CrossRef
Melero, R., Ibánez, D., Tiemblo, C., Díez, B., del Arco, J., García, M. Á., & Castro, M. B. (2011). [Estudio Psoriafarm Bizkaia: características más relevantes]. Pharmaceutical Care España, 13(2), 74–90.
Palijan, T. Z., Kovacevic, D., Koic, E., Ruzic, K., & Dervinja, F. (2011). The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis. Collegium Antropologicum, 35(2), 81–85. PubMed
Zeljko-Penavic, J., Situm, M., Simic, D., & Vurnek-Zivkovic., M. (2010). Quality of life in psoriatic patients and the relationship between type I and type II psoriasis. Collegium Antropologicum, 34(1), 195–198. PubMed
Tennvall, G., Hjortsberg, C., Bjarnason, A., Gniadecki, R., Heikkila, H., & Jemec, G. B. et al. (2013). Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three nordic countries. Acta Dermato-Venereologica, 93, 442–445. CrossRef
- Health-related quality of life in patients with psoriasis: a systematic review of the European literature
- Springer International Publishing